PeptiDream Inc. (4587) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for PeptiDream Inc. (4587:JPX), powered by AI.

Current Price
¥925.1
P/E Ratio
-31.9
Market Cap
119.6B
Sector
Healthcare
What is the PeptiDream Inc. stock price forecast?

PeptiDream Inc. is currently trading at ¥925.1. View real-time AI analysis on Alpha Lenz.

What is PeptiDream Inc. insider trading activity?

View the latest insider trading data for PeptiDream Inc. on Alpha Lenz.

What is PeptiDream Inc.'s P/E ratio?

PeptiDream Inc.'s P/E ratio is -31.9.

PeptiDream Inc.

JPX · 4587
¥925-7(-0.79%)Market closedJPX regular session 09:00–15:00 JST
Ask about PeptiDream Inc.'s future dividend policy...
Alpha Chat Insight

PeptiDream Inc. trades at a P/E of -31.9 (undervalued) with modest ROE of -6.9%.

Ask for details

Company Overview

PeptiDream Inc. is a biotechnology firm that plays a pivotal role in the healthcare and pharmaceutical sectors. The company is particularly known for its innovative peptide drug discovery platform. This novel platform enables the development of highly specific and potent peptide-based therapeutics, targeting a broad range of medical conditions, from cancer to metabolic disorders. PeptiDream’s technology, which focuses on using advanced techniques in molecular biology and chemistry, allows for the design of peptides that can interact with targets that are traditionally difficult to engage with small molecules or antibodies. Operating within the competitive and rapidly-evolving biotechnology industry, PeptiDream Inc. frequently collaborates with global pharmaceutical companies to co-develop treatments and bring new drugs to market. These partnerships are crucial for enhancing the development pipeline and expanding the potential impact of their therapeutic discoveries. Established as a leader in peptide drug design, PeptiDream contributes significantly to medical advancements and offers substantial potential for introducing novel therapeutic solutions to unmet clinical needs. Its work in addressing complex biological targets underscores its importance in driving innovation within the pharmaceutical research community.

CEODr. Patrick Crawford Reid Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees757

Company Statistics

FY 2025

Profile

¥119,620,742,849Market Cap
¥18,521,234,000Revenue
0.00Shares Out
757Employees

Margins

40.61%Gross
-14.50%EBITDA
-27.07%Operating
-28.68%Pre-Tax
-20.24%Net

Valuation

-31.91P/E
2.32P/B
6.46EV/Sales
-40.21EV/EBITDA
-7.96P/FCF

Growth (CAGR)

-11.65%Rev 3Yr
9.66%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-4.42%ROA
-6.92%ROE
-5.67%ROIC

Financial Health

¥28,682,933,000Cash & Cash Equivalents
¥-3,178,011,000Net Debt
49.50%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

PeptiDream Inc. (ticker: 4587) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 757 employees. Market cap is $119.6B.

The current price is 925.1 with a P/E ratio of -31.91x and P/B of 2.32x.

ROE is -6.92% and operating margin is -27.07%. Annual revenue is $18.5B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
PeptiDream Inc. (4587) Stock Forecast 2026 ¥925.1 — Price, Financials & Analyst Targets | Alpha Lenz